

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BioStratum, Inc.	05/28/2007
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BioStratum AB
<b>Street Address:</b>	Sandhamnsgatan 23
<b>City:</b>	Stockholm
<b>State/Country:</b>	SWEDEN
<b>Postal Code:</b>	115 28
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	10834525
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)913-0002
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	312-913-0001
<b>Email:</b>	Oslick@mbhb.com
<b>Correspondent Name:</b>	McDonnell Boehnen Hulbert & Berghoff LLP
<b>Address Line 1:</b>	300 South Wacker Drive
<b>Address Line 2:</b>	Suite 3100
<b>Address Line 4:</b>	Chicago, ILLINOIS 60606
<b>ATTORNEY DOCKET NUMBER:</b>	03-390-US
<b>NAME OF SUBMITTER:</b>	Sherri L. Oslick, Ph.D.
<b>Total Attachments: 1</b> source=03-390-US Assignment (Executed) BioStratum, Inc. to BioStratum AB#page1.tif	

CH \$40.00 10834525

**PATENT APPLICATION ASSIGNMENT**

WHEREAS, BioStratum, Inc. ("ASSIGNOR"), a Delaware corporation having its principal office at BioStratum, Inc., P.O. Box 575, Alamance, NC 27201, United States of America, owns the following patent applications:

U.S. Patent Application Serial No. 10/834,525, filed 29 April 2004 entitled "ApoCIII and the Treatment and Diagnosis of Diabetes" and

European Patent Application No. 04751089.6 filed 29 April 2004 entitled "ApoCIII and the Treatment and Diagnosis of Diabetes"; and

WHEREAS, BioStratum AB. ("ASSIGNEE"), a Swedish corporation, having its principal office at Sandhamnsgatan 23, 115 28 Stockholm, Sweden, desires to acquire the entire right, title and interest in the Application;

NOW, THEREFORE, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers all rights, title and interest in the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues, extensions, or other patent applications claiming the benefit of the filing date of the Applications, to ASSIGNEE, its successors and assigns.

ASSIGNOR hereby authorizes and requests the respective Commissioner of Patents and Trademarks to issue any Letters Patent which may issue for the Application, including any divisions, continuations, continuations-in-part, reexaminations, reissues or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and that ASSIGNOR will execute such additional writings and do such additional acts as ASSIGNEE, its successors and assigns, may deem necessary or desirable to perfect its enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reissued, reexamined or extended Letters Patent that may issue from the Application.

BioStratum AB


Date: \_\_\_\_\_

May 25

Signature: \_\_\_\_\_

Printed Name: \_\_\_\_\_

Title: \_\_\_\_\_



EUGEN STEWER

CHAIRMAN, CEO